Skye Bioscience, Inc.
SKYE · NASDAQ
9/30/2025 | 6/30/2025 | 3/31/2025 | 12/31/2024 | |
|---|---|---|---|---|
| Revenue | $0 | $0 | $0 | $0 |
| % Growth | – | – | – | – |
| Cost of Goods Sold | $0 | $0 | $0 | $0 |
| Gross Profit | $0 | $0 | $0 | $0 |
| % Margin | – | – | – | – |
| R&D Expenses | $9 | $14 | $7 | $8 |
| G&A Expenses | $4 | $4 | $5 | $5 |
| SG&A Expenses | $4 | $4 | $5 | $5 |
| Sales & Mktg Exp. | $0 | $0 | $0 | $0 |
| Other Operating Expenses | $0 | $0 | $0 | -$2 |
| Operating Expenses | $13 | $18 | $12 | $11 |
| Operating Income | -$13 | -$18 | -$12 | -$11 |
| % Margin | – | – | – | – |
| Other Income/Exp. Net | $1 | $1 | $1 | $1 |
| Pre-Tax Income | -$13 | -$18 | -$11 | -$10 |
| Tax Expense | $0 | $0 | $0 | $0 |
| Net Income | -$13 | -$18 | -$11 | -$10 |
| % Margin | – | – | – | – |
| EPS | -0.32 | -0.44 | -0.28 | -0.24 |
| % Growth | 27.3% | -57.1% | -16.7% | – |
| EPS Diluted | -0.32 | -0.44 | -0.28 | -0.24 |
| Weighted Avg Shares Out | 40 | 40 | 40 | 40 |
| Weighted Avg Shares Out Dil | 40 | 40 | 40 | 40 |
| Supplemental Information | – | – | – | – |
| Interest Income | $0 | $1 | $1 | $1 |
| Interest Expense | $0 | $0 | $0 | – |
| Depreciation & Amortization | $0 | $0 | $0 | $0 |
| EBITDA | -$13 | -$17 | -$11 | -$10 |
| % Margin | – | – | – | – |